{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-041591","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.388677+00:00","generated_at":"2026-06-29T21:51:45.263353+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcus Biosciences reports Q2 net loss of $76M, cash $805M; appoints Nicole Lambert to board","bullets":["Net loss $76.0M for Q2 2021 vs $45.1M in Q2 2020; six-month net loss $148.6M.","Collaboration revenue $9.5M in Q2 2021 vs $1.8M; R&D expenses $68.8M (up from $35.7M).","Cash and investments $805.1M as of June 30, 2021 vs $735.1M at Dec 31, 2020; funded at least through 2023.","Appointed Nicole Lambert to Board of Directors, President of Myriad Genetic Laboratories.","Pipeline: HIF-2α inhibitor AB521 enters clinic in Q4 2021; domvanalimab combination data promising; randomized ARC-8 enrollment to complete by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-041591","json":"https://secwatch.observer/filing/0001564590-21-041591.json","markdown":"https://secwatch.observer/filing/0001564590-21-041591.md","text":"https://secwatch.observer/filing/0001564590-21-041591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021041591/0001564590-21-041591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021041591/rcus-8k_20210803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:51:45.263353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9275ab94d","claim":"Nicole Lambert was appointed as Director at Arcus Biosciences, Inc..","evidence_excerpt":"On August 3, 2021, the Board of Directors of Arcus Biosciences, Inc. appointed Nicole Lambert to the Board as a Class II Director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021041591/0001564590-21-041591-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}